Even though daily low-dose aspirin raises the risk of bleeding in older adults, having a blood cell mutation called CHIP doesn’t make that risk any higher or lower than it already is.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis could determine whether the lack of interaction between aspirin and CHIP on bleeding is consistent across multiple trials with standardized CHIP detection.
A systematic review and meta-analysis of all RCTs with pre-specified CHIP subgroup analysis (VAF ≥2%) and adjudicated bleeding outcomes, pooling interaction p-values for aspirin effect on bleeding by CHIP status across ≥5 trials.
An RCT could definitively test whether aspirin’s bleeding risk is the same in CHIP carriers and non-carriers by randomizing within CHIP strata.
A multicenter, double-blind RCT of 4,000 adults aged 70+ with and without CHIP (VAF ≥2%), stratified by CHIP status and randomized 1:1 to aspirin or placebo for 5 years, with primary endpoint: composite of ISTH-defined major bleeding events.
A prospective cohort could assess whether aspirin use modifies the bleeding risk associated with CHIP over time in real-world settings.
A prospective cohort of 12,000 adults aged 70+ with baseline CHIP status (VAF ≥2%) and aspirin use recorded at baseline and annually, followed for 7 years with blinded adjudication of bleeding events, adjusting for comorbidities and concomitant medications.
A case-control study could compare aspirin exposure in individuals with and without bleeding, stratified by CHIP status, to estimate interaction effects.
A matched case-control study of 800 adults aged 70+ with adjudicated major bleeding (cases) and 1,600 controls without bleeding, stratified by CHIP status (positive/negative), with detailed history of aspirin use (dose, duration, timing) and adjustment for indication bias.
A cross-sectional study could estimate the prevalence of aspirin use among those with CHIP and bleeding, but cannot determine temporal relationships.
A single-timepoint survey of 5,000 adults aged 70+ with known CHIP status and recent bleeding history, measuring current aspirin use and correlating it with bleeding severity and VAF level.